ArticleBiology2026
Regulation of PCSK9 During Oxidized LDL-Induced Foam Cell Formation in RAW264.7 Cells.
Article in Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is traditionally known for regulating plasma LDL cholesterol levels via LDL receptor degradation. This exploratory study examined the association between chemically induced changes in Krüppel-like factor 2 (KLF2), a vasoprotective transcription factor, and PCSK9 expression under ox-LDL-induced conditions in RAW264.7 cells. In silico molecular docking was also performed to determine whether GGTI298 could adopt a predicted binding pose within PCSK9. KLF2 was modulated by adding GGPP (a chemical inhibitor) and GGTI298 (a chemical activator) to the monocytes. Quantitative real-time PCR and immunocytochemistry were used to assess KLF2 and PCSK9 expression. Molecular docking was performed to examine the interaction between GGTI298 and PCSK9 using computational tools. Results show that ox-LDL significantly increased PCSK9 expression in monocytes during foam cell formation. However, GGPP significantly increased PCSK9 expression. In contrast, GGTI298 markedly reduced PCSK9 expression, suggesting a negative regulatory role of KLF2. Docking studies revealed that GGTI298 binds to the PCSK9 catalytic domain with favorable binding energy, forming stable hydrogen bonds and hydrophobic interactions with key amino acid residues, indicating potential interference with PCSK9 function. GGTI298 suppresses PCSK9 expression during foam cell formation, highlighting its protective role. The dual ability of GGTI298 to enhance KLF2 expression and directly bind to PCSK9 underscores its potential as a therapeutic agent for managing foam cell formation that leads to atherosclerosis. The findings demonstrate an inverse association between KLF2 and PCSK9 expression following chemical treatment under ox-LDL-induced conditions. However, direct KLF2-dependent regulation of PCSK9, direct GGTI298-PCSK9 binding, and functional inhibition of PCSK9 were not established and require further genetic, biochemical, and functional validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.